{"entity":{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","aka":[],"tldr":"Evergreen Theragnostics manufactures radioactive cancer medicines for other companies and develops its own imaging agent for neuroendocrine tumours and a treatment for small cell lung cancer. Lantheus bought it in April 2025.","summary":"Evergreen Theragnostics is a Springfield, New Jersey radiopharmaceutical company combining contract development and manufacturing (CDMO) services with proprietary products. Its facility, completed in October 2021, has produced clinical material for partners including Clovis Oncology (225Ac FAP-2286), Clarity (copper theranostics), MTTI and Precirix (CAM-H2). Proprietary programmes include OCTEVY, a registrational-stage PET diagnostic for neuroendocrine tumours, and EVG321, a CCK2 receptor-targeted radioligand licensed from the Medical University of Innsbruck in May 2024 for small cell lung cancer, with the CCK2-VIEW phase 2 trial opened in the EU in October 2024. In January 2025 Lantheus agreed to acquire Evergreen for USD 250 million upfront and up to USD 752.5 million in milestones, to become a fully integrated radiopharmaceutical company. Lantheus completed the acquisition on 1 April 2025, paying about USD 275 million in cash at closing (the upfront payment plus a USD 25 million milestone), with up to USD 727.5 million in further milestones possible.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.evergreentgn.com/"},{"label":"Lantheus acquisition release","url":"https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/"},{"label":"Lantheus Form 8-K: acquisition completed (April 2025)","url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401d8k.htm"},{"label":"News","url":"https://www.evergreentgn.com/news/"}],"tags":[],"related":[],"cancers":["neuroendocrine","sclc"],"sections":["radiopharma"],"technologies":["radioligand-therapy","pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Venture financing before the acquisition not fetched and omitted. Completion date and closing payment come from Lantheus's Form 8-K filed 1 April 2025; the company site carries a banner stating that Lantheus has completed the acquisition."],"hq":"Springfield, NJ","country":"US","companyType":"radiopharma","website":"https://www.evergreentgn.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"amountUsd":250000000,"source":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401d8k.htm","note":"USD 250 million upfront plus up to USD 752.5 million in milestones; all-cash, announced 28 January 2025. Completed 1 April 2025, when Lantheus paid about USD 275 million including a USD 25 million milestone, per its Form 8-K"}],"acquiredBy":"lantheus"},"route":"/companies/evergreen-theragnostics/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"company":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/"}]}}